A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2002
12/05/2002	WO2002096867A2 Inhibitors of protein kinase for the treatment of disease
12/05/2002	WO2002096866A2 Thiolalkyl benzoic acid derivatives
12/05/2002	WO2002096864A1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments
12/05/2002	WO2002096857A1 Novel retinoid derivatives and methods for producing said compounds and an anti-cancer pharmaceutical composition comprising said compounds
12/05/2002	WO2002096455A2 Use of polyclonal immunoglobulins
12/05/2002	WO2002096430A1 Cephalosporin derivatives as anti-cancer agents
12/05/2002	WO2002096427A1 Pyrimidine derivatives as selective inhibitors of cox-2
12/05/2002	WO2002096426A1 Hydantion derivatives as inhibitors of matrix metalloproteinases
12/05/2002	WO2002096419A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
12/05/2002	WO2002096413A1 Composition comprising demethylcantharidin in combination with platinum-containing anticancer agents and use thereof
12/05/2002	WO2002096408A1 Coenzyme q and eicosapentaenoic acid (epa)
12/05/2002	WO2002096400A1 Medicament which can be used for the treatment of cancer
12/05/2002	WO2002096396A1 Fine inorganic particles having drug included therein, method for preparation thereof and pharmaceutical preparation comprising fine inorganic particles having drug included therein
12/05/2002	WO2002096367A2 Targeted multivalent macromolecules
12/05/2002	WO2002096366A2 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
12/05/2002	WO2002096363A2 Method for treating fibrotic diseases or other indications
12/05/2002	WO2002096361A2 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
12/05/2002	WO2002096360A2 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
12/05/2002	WO2002096358A2 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
12/05/2002	WO2002096357A2 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
12/05/2002	WO2002096348A2 Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
12/05/2002	WO2002096203A1 Stem cell differentiation
12/05/2002	WO2002083675A3 Inhibitors of akt activity
12/05/2002	WO2002081415A3 Method for inhibiting metap2
12/05/2002	WO2002080854A3 Compositions and methods for the prevention and treatment of human prostate cancer
12/05/2002	WO2002078720A3 Antibiotics from bacteria isolated from amphibian skin
12/05/2002	WO2002076400A3 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
12/05/2002	WO2002074036A3 Substituted benzopyranones as telomerase inhibitors
12/05/2002	WO2002070557A3 Nuclear hormone receptor ligand binding domain
12/05/2002	WO2002068470A3 Interferon-alpha induced gene
12/05/2002	WO2002066450A3 Anthrone derivatives and their use as ink inhibitors
12/05/2002	WO2002065978A3 Functional agent for decomposing nicotine and method of preparing the same
12/05/2002	WO2002064757A3 Influenza viruses with enhanced transcriptional and replicational capacities
12/05/2002	WO2002064547A3 Isophthalic acid derivatives as matrix metalloproteinase inhibitors
12/05/2002	WO2002062798A3 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
12/05/2002	WO2002060426A3 Compounds regulating cell proliferation and differentiation
12/05/2002	WO2002059116A3 Antimicrobial quinolone derivatives and use of the same to treat bacterial infections
12/05/2002	WO2002055675A8 Ancillary composition for the preparation of committed mature dendritic cells
12/05/2002	WO2002053110A3 Pharmaceutical preparation for douches and/or irrigations of natural or pathological cavities in the human body
12/05/2002	WO2002047728A3 Treatment of posterior capsule opacification
12/05/2002	WO2002042321A3 Mixed fibrils
12/05/2002	WO2002036073A3 Receptor antagonist-lipid conjugates and delivery vehicles containing same
12/05/2002	WO2002028902A3 Nectin polypeptides, polynucleotides, methods of making and use thereof
12/05/2002	WO2002020766A3 G-csf analog compositions and methods
12/05/2002	WO2002016413A3 Cripto tumour polypeptide
12/05/2002	WO2002013862A3 Method and composition for altering a b cell mediated pathology
12/05/2002	WO2002013861A3 Method and composition for altering a t cell mediated pathology
12/05/2002	WO2002006453A3 Regulation of human desc1-like serine protease
12/05/2002	WO2001097608A3 Cyk-4 polypeptides, dna molecules encoding them and their use in screening methods
12/05/2002	WO2001093909A3 Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor
12/05/2002	WO2001093840A2 Ligands of integrin receptors
12/05/2002	WO2001092491A3 Mammalian protein phosphatases identified by in-silico analysis
12/05/2002	WO2001060397A9 Uses of agonists and antagonists to modulate activity of tnf-related molecules
12/05/2002	WO2001049743A9 Methods of modulation of the immune system
12/05/2002	WO2001032926A3 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
12/05/2002	WO2001032685A9 Gene expression directed by a super-psa promoter
12/05/2002	WO2001021796A9 Gl50 molecules and uses therefor
12/05/2002	WO2001019408A9 Nucleic acids encoding polyepitope polypeptides
12/05/2002	US20020183808 Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant
12/05/2002	US20020183524 Preparations and use of an Ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester
12/05/2002	US20020183514 Useful in the treatment and control of solid tumors
12/05/2002	US20020183513 Tricyclic alkylhydroxamate derivatives
12/05/2002	US20020183503 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of immunological, infectious, inflammatory and cancer disorders
12/05/2002	US20020183500 Nucleotide sequence coding polypeptide for use in the treatment, diagnosis, classification and imaging of lung cancer
12/05/2002	US20020183485 Nucleotide sequences coding receptor protein for use in the treatment of hypertriglyceridaemia, inflammation, cachexia, infections and tumors
12/05/2002	US20020183394 Pharmaceutical compositions of fenretinide having increased bioavailability and methods of using the same
12/05/2002	US20020183385 Administering a therapeutically effective amount of arsenic compounds to a mammal for treating solid tumor
12/05/2002	US20020183384 Administering sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt for therapy of disease or a disorder responsive to inhibition of nuclear factor- kappa B (NF- kappa B)
12/05/2002	US20020183381 Inhibitor for neovasculation, cell multiplication, lumen formation and FGF
12/05/2002	US20020183365 Therapy or ameliorating an indication of the invention in an animal, including a human, comprising administering heteroaryl compond
12/05/2002	US20020183363 Reacting benzimidazole compound with m-chloroperoxybenzoic acid in a solvent selected from the group consisting of acetone and acetone/water mixture; raising the pH of the reaction mixture; crystals are separated
12/05/2002	US20020183362 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation
12/05/2002	US20020183346 Tricyclic androgen receptor modulator compounds and methods
12/05/2002	US20020183323 For therpay of inflammatory bowel disease, cerebral ischemia and arthritis, adult respiratory distress syndrome (ARDS) and myocarditis, as adjuvants to short term immunosuppression in transplant therapy
12/05/2002	US20020183319 For therapy of blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer
12/05/2002	US20020183318 Novel derivatives of flavones, xanthones and coumarins
12/05/2002	US20020183314 For therapy of acne, male- pattern baldness, sexual dysfunction, impotence, wasting diseases, hirsutism, hypogonadism, prostatic hyperplasia, osteoporosis, cancer cachexia, and hormone-dependent cancers
12/05/2002	US20020183291 Use of an aromatase inhibitor selected from exemestane, anastrozole, letrozole and fadrozole in the preparation of a medicament for use in treating gynecomastia in a patient undergoing treatment with antiandrogen
12/05/2002	US20020183289 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses
12/05/2002	US20020183271 Administering to the patient a human MDA-7 polypeptide or a nucleic acid expressing the human MDA-7 polypeptide in eukaryotic cells, whereby the MDA-7 polypeptide inhibits angiogenesis in the patient
12/05/2002	US20020183269 Novel compounds
12/05/2002	US20020183266 Combination comprising combretastatin and anticancer agents
12/05/2002	US20020183263 Nutritional preparation comprising ribose and medical use thereof
12/05/2002	US20020183259 Terminally-branched polymeric linkers and polymeric conjugates containing the same
12/05/2002	US20020183256 Cytostatic-integrin conjugates having specifically cleavable linking units
12/05/2002	US20020183253 Effecting an increase in the amount of an endostatin in ocular tissues of an individual afflicted with ocular neovascularization to an ocular neovascularization inhibiting effective amount
12/05/2002	US20020183242 Peptide antiangiogenic drugs
12/05/2002	US20020183240 Antineoplastic combinations
12/05/2002	US20020182703 Human defensin polypeptide Def-X, genomic DNA and cDNA, composition containing them and applications to diagnosis and to therapeutic treatment
12/05/2002	US20020182683 Vascular endothelial growth factor 2
12/05/2002	US20020182681 Peptide for use in treatment of cancer, parkinson's and metabolic disorders
12/05/2002	US20020182671 Polypeptide for use in the treatment, diagnosis, and prevention of cell proliferative, autoimmune/inflammatory, neurological and gatrointestinal disorders
12/05/2002	US20020182665 Increased recovery of active proteins
12/05/2002	US20020182643 Detecting preferential ligands in cell; obtain cell, incubate with reporter molecules, detect reporter in cell
12/05/2002	US20020182614 Expression analysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
12/05/2002	US20020182274 Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract
12/05/2002	US20020182269 Cucumis melo extract coated and/or microencapsulated in a fat-soluble agent based on a fatty substance
12/05/2002	US20020182268 Plant extracts, especially for breast cancer
12/05/2002	US20020182265 Lubricious coatings for substrates
12/05/2002	US20020182221 Recombinant papillomavirus vaccine and method for production and treatment

1 ... 1631 1632 1633 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 ... 2211